The estimated Net Worth of Charles R. Kummeth is at least $134 Milione dollars as of 15 August 2023. Mr. Kummeth owns over 17,632 units of Bio-Techne Corp stock worth over $94,577,515 and over the last 11 years he sold TECH stock worth over $28,412,720. In addition, he makes $11,483,800 as President, Chief Executive Officer e Director at Bio-Techne Corp.
Sign up
Mr. Kummeth TECH stock SEC Form 4 insiders trading
Charles has made over 37 trades of the Bio-Techne Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 17,632 units of TECH stock worth $1,295,776 on 15 August 2023.
The largest trade he's ever made was exercising 616,676 units of Bio-Techne Corp stock on 30 June 2023 worth over $16,434,415. On average, Charles trades about 27,922 units every 31 days since 2013. As of 15 August 2023 he still owns at least 1,286,944 units of Bio-Techne Corp stock.
You can see the complete history of Mr. Kummeth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Kummeth biography
Charles R. Kummeth is President, Chief Executive Officer, Director of Bio-Techne Corporation. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. from September 2011. He was President of that company’s Laboratory Consumables Division from 2009 to September 2011. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as the Vice President of the company’s Medical Division from 2006 to 2008. Mr. Kummeth also serves on the board of one other public company, Gentherm, Inc., developer of thermal management technologies.
What is the salary of Charles Kummeth?
As the President, Chief Executive Officer e Director of Bio-Techne Corp, the total compensation of Charles Kummeth at Bio-Techne Corp is $11,483,800. There are no executives at Bio-Techne Corp getting paid more.
How old is Charles Kummeth?
Charles Kummeth is 60, he's been the President, Chief Executive Officer e Director of Bio-Techne Corp since 2014. There are 7 older and 12 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.
What's Charles Kummeth's mailing address?
Charles's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Insiders trading at Bio-Techne Corp
Over the last 21 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey e John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.
What does Bio-Techne Corp do?
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
What does Bio-Techne Corp's logo look like?
Complete history of Mr. Kummeth stock trades at Bio-Techne Corp, Gentherm Inc e Orthofix Medical Inc
Bio-Techne Corp executives and stock owners
Bio-Techne Corp executives and other stock owners filed with the SEC include:
-
Charles Kummeth,
President, Chief Executive Officer, Director -
Charles R. Kummeth,
CEO, Pres & Director -
James Hippel,
Chief Financial Officer, Executive Vice President - Finance -
David Eansor,
President - Protein Sciences -
Kim Kelderman,
President - Diagnostics and Genomics -
Brenda Furlow,
Senior Vice President, General Counsel, Corporate Secretary -
James T. Hippel,
Exec. VP of Fin. & CFO -
Norman David Eansor,
Pres of Protein Sciences Segment -
Kim Kelderman,
Pres of Diagnostics & Genomics -
Brenda S. Furlow J.D.,
Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Robert Baumgartner,
Independent Chairman of the Board -
Rupert Vessey,
Independent Director -
John Higgins,
Independent Director -
Randolph Steer,
Independent Director -
Roeland Nusse,
Independent Director -
Alpna Seth,
Independent Director -
Joseph Keegan,
Independent Director -
David Clair,
IR Contact Officer -
Julie Bushman,
Independent Director -
Kevin Smyth,
Sr. VP & Chief Digital Officer -
Luca Cicchetti,
Managing Director -
Brenda Everson,
Sr. VP of HR -
Kevin S. Gould,
Sr. VP of Diagnostics Reagents Division -
Struan Robertson,
VP of HR -
Robert M. Gavin,
VP of Corp. Devel. -
Gerry Andros,
VP of Sales and Marketing -
Karen A Holbrook,
Director -
Roger C Lucas,
-
Charles A Dinarello,
-
J. Fernando Bazan,
Chief Technical Officer -
Robert M. Gavin,
Sen. VP Protein Platforms -
Kevin S Gould,
SVP Clinical Controls -
Kevin J Reagan,
Senior VP Biotech -
Gregory J Melsen,
VP Finance and CFO -
Thomas E Oland,
President -
Howard V Oconnell,
Director -
Marcel Veronneau,
Vice Pres-Hematology Oper. -
James A Weatherbee,
Chief Scientific Officers -
Monica Tsang,
Vice President of Research -
Christopher S Henney,
Director -
G A Herbert,
Director -
Harold J Wiens,
-
William Geist,
PRESIDENT, PROTEIN SCIENCES -
Shane Bohnen,
SVP - General Counsel -
Matthew Mc Manus,
President - DGS -
Judith V Klimovsky,
Director